Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno
Mason's new title will be senior vice president of Lilly and president of Lilly Diabetes. He will report to Ricks and join Lilly's executive committee.
"Mike and Enrique have partnered closely together over the last six years, and Mike has been a significant part of Lilly's work to grow our portfolio of medicines and renew our commitment to the diabetes community," said
Mason oversees Lilly's connected care business, which leverages technology to enhance insulin delivery and improve the user experience. He also has led the company's efforts to improve insulin affordability, including the creation of the Lilly Diabetes Solution Center, to support people in need of less expensive alternatives to their insulin. This work will continue under Mason's leadership.
Mason will assume his new role
"Enrique has had a remarkable career, making significant contributions in every role he's had at Lilly," said Ricks. "In 2009, he took the helm of Lilly Diabetes and reestablished us as a leader in diabetes care with the broadest and fastest growing portfolio of medicines in the industry. He is a friend and trusted advisor to so many of us at the company. His energy, optimism and thirst for excellence will be missed."
A native of
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels. C-LLY
This press release contains forward-looking statements about leadership changes and reflects Lilly's current beliefs. There are risks and uncertainties related to leadership changes. For discussion of important risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the
View original content to download multimedia:http://www.prnewswire.com/news-releases/enrique-conterno-senior-vice-president-and-president-of-lilly-diabetes-and-lilly-usa-to-retire-at-end-of-year-mike-mason-to-succeed-conterno-300943583.html